Publications by authors named "K V Kowdley"
Background And Aims: Primary biliary cholangitis (PBC) is a rare, progressive liver disease. Obeticholic acid (OCA) received accelerated approval for treating patients with PBC in whom ursodeoxycholic acid (UDCA) failed, based on a surrogate endpoint of reduction in alkaline phosphatase. Analysis of the long-term safety extension with 2 external control groups demonstrated a significant increase in event-free survival in OCA-treated patients.
View Article and Find Full Text PDFPrimary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape.
Am J Gastroenterol
January 2025
Article Synopsis
- Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are rare chronic liver diseases that can lead to severe liver damage if not treated.
- Ursodeoxycholic acid is the traditional first-line treatment for PBC, with new medications like obeticholic acid and fibrates as second-line options, while PSC currently has no approved treatments except for liver transplants.
- Recent advances include two new FDA-approved drugs for PBC and ongoing research into additional therapies for both PBC and PSC, showing promise for future treatments.
Article Synopsis
- The study looked at how patients with a liver disease called primary biliary cholangitis (PBC) respond to a treatment called ursodeoxycholic acid (UDCA).
- It found that many patients (33%) didn’t have a good response after one year, and those who lost their good response had a higher chance of needing a liver transplant or dying.
- The research showed that staying or getting back to a good response is important for improving long-term health.
Article Synopsis
- Tirzepatide is the first dual incretin receptor activator approved for treating type II diabetes and obesity.
- It has shown benefits in reducing liver fat without known cases of liver damage from its use.
- However, a case of elevated liver enzymes was reported in a 37-year-old woman with metabolic syndrome after using tirzepatide.